US pharma giant Merck & Co (NYSE: MRK) and Endocyte (Nasdaq: ECYT) have withdrawn their conditional marketing authorization applications (CMA) from the European Medicines Agency for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).
The companies’ decision was based on further review of interim data from the PROCEED trial. Study enrollment was suspended earlier this month based on the Data Safety Monitoring Board’s (DSMB) recommendation that the study be stopped because vintafolide in combination with PLD versus PLD alone did not meet the pre-specified criteria for progression-free survival to allow continuation of the study (The Pharma Letter May 3). That news caused Endocyte’s share to nose dive 62% to $6.65. The firm’s shares fell 6% in after-hours trading to $6.10 last night. Merck acquired rights to the drug in a licensing deal worth up to $1 billion in 2012.
The DSMB did not identify any safety concerns for the patients enrolled in the PROCEED trial. The companies will take steps to terminate the PROCEED trial and will provide investigators with instructions to conclude the trial. The study results will be presented in a future scientific congress.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze